{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:45:04Z","timestamp":1792701904831,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D). Retatrutide may also address key chronic kidney disease (CKD)-related pathophysiological pathways. Mechanism-of-action studies are needed to understand its effects on kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TRANSCEND-CKD is a double-blind, placebo-controlled, Phase 2b mechanistic study evaluating the efficacy of retatrutide in adults with overweight\/obesity and CKD [estimated glomerular filtration rate (eGFR) 25\u201375\u00a0mL\/min\/1.73 m2], with and without T2D. Participants were randomized 1:1 to once-weekly retatrutide maximum tolerated dose up to 12\u00a0mg or matched placebo. The primary objective is to evaluate the effect of retatrutide versus placebo on change in measured glomerular filtration rate (mGFR) by iohexol clearance from baseline to Week 24. Additional objectives include changes in magnetic resonance imaging\u2013assessed kidney hemodynamic and volumetric measurements, including perirenal and renal sinus fat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 367 participants screened, 146 were randomized to study interventions. The mean age was 65.1 years [standard deviation (SD) 10.6], 45.2% were female and 69.9% were White. The mean weight was 101.1\u00a0kg (SD 20.6) and body mass index 35.7\u00a0kg\/m2 (SD 6.1). Participants with T2D (37.7%) had a mean HbA1c of 7.1% (SD 1.1%), while HbA1c was 5.7% (SD 0.3%) in participants without T2D. The mean mGFR was 49.3\u00a0mL\/min\/1.73 m2 (SD 19.0), cystatin C\u2013based eGFR was 49.6\u00a0mL\/min\/1.73 m2 (SD 13.2) and creatinine-based eGFR was 64.2\u00a0mL\/min\/1.73 m2 (SD 17.8). The median baseline urine albumin-to-creatinine ratio was 14.0\u00a0mg\/g (interquartile range 6.0\u201369.0). A total of 21.8% of participants were treated with sodium-glucose cotransporter-2 inhibitors at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TRANSCEND-CKD is designed to provide mechanistic insights on the effects of retatrutide on kidney function and structure, and to inform clinical findings in the ongoing cardio-kidney outcome trial TRIUMPH-Outcomes (NCT06383390).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration Number<\/jats:title>\n                    <jats:p>NCT05936151<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf230","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:51:07Z","timestamp":1761655867000},"page":"1058-1068","source":"Crossref","is-referenced-by-count":6,"title":["Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"first","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department of Clinical Pharmacy and Pharmacology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H","family":"van Raalte","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathijs C","family":"Bunck","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peikun","family":"Wu","sequence":"additional","affiliation":[{"name":"R&G US , Somerset, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Tunali","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvonko","family":"Milicevic","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Koeneman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026052900265723200_bib1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/j.jrn.2025.07.004","article-title":"Evaluation and management of obesity in chronic kidney disease","volume":"35","author":"Friedman","year":"2025","journal-title":"J Ren Nutr"},{"key":"2026052900265723200_bib2","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"key":"2026052900265723200_bib3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026052900265723200_bib4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026052900265723200_bib5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2026052900265723200_bib6","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052900265723200_bib7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026052900265723200_bib8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/dc24-1773","article-title":"Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1-5 clinical trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"key":"2026052900265723200_bib9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1681\/ASN.0000000764","article-title":"Kidney parameters with tirzepatide in obesity with or without type 2 diabetes","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026052900265723200_bib10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026052900265723200_bib11","doi-asserted-by":"publisher","first-page":"E747","DOI":"10.1152\/ajpendo.00374.2023","article-title":"Incretin and glucagon receptor polypharmacology in chronic kidney disease","volume":"326","author":"McFarlin","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026052900265723200_bib12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"2026052900265723200_bib13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"2026052900265723200_bib14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052900265723200_bib15","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.ekir.2025.03.049","article-title":"The effect of retatrutide on kidney parameters in participants with type 2 diabetes mellitus and\/or obesity","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026052900265723200_bib16","doi-asserted-by":"publisher","first-page":"F225","DOI":"10.1152\/ajprenal.1995.269.2.F225","article-title":"Influence of glucagon on GFR and on urea and electrolyte excretion: direct and indirect effects","volume":"269","author":"Ahloulay","year":"1995","journal-title":"Am J Physiol"},{"key":"2026052900265723200_bib17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/BF00280519","article-title":"The effect of glucagon infusion on kidney function in short-term insulin-dependent juvenile diabetics","volume":"19","author":"Parving","year":"1980","journal-title":"Diabetologia"},{"key":"2026052900265723200_bib18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.kint.2024.11.003","article-title":"Semaglutide and kidney function: direct kidney protection or an artifact?","volume":"107","author":"Ayoub","year":"2025","journal-title":"Kidney Int"},{"key":"2026052900265723200_bib19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.kint.2024.06.029","article-title":"Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium","volume":"106","author":"Ebert","year":"2024","journal-title":"Kidney Int"},{"key":"2026052900265723200_bib20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026052900265723200_bib21","article-title":"Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1)","author":"International Council for Harmonisation"},{"key":"2026052900265723200_bib22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"2026052900265723200_bib23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/jdi.12956","article-title":"Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagon-like peptide-1 on glomeruli and tubules in diabetic rats","volume":"10","author":"Yin","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2026052900265723200_bib24","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s13300-020-00904-z","article-title":"Comparison of blood glucose variability between exenatide and biphasic insulin aspart 30 in Chinese participants with type 2 diabetes inadequately controlled with Metformin monotherapy: a multicenter, open-label, randomized trial","volume":"11","author":"Wang","year":"2020","journal-title":"Diabetes Ther"},{"key":"2026052900265723200_bib25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026052900265723200_bib26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2026052900265723200_bib27","doi-asserted-by":"publisher","first-page":"707126","DOI":"10.3389\/fendo.2021.707126","article-title":"Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases","volume":"12","author":"Hammoud","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026052900265723200_bib28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/db23-0201","article-title":"High doses of exogenous glucagon stimulate insulin secretion and reduce insulin clearance in healthy humans","volume":"73","author":"Gray","year":"2024","journal-title":"Diabetes"},{"key":"2026052900265723200_bib29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diabres.2018.10.004","article-title":"Glucagon revisited: coordinated actions on the liver and kidney","volume":"146","author":"Bankir","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2026052900265723200_bib30","doi-asserted-by":"publisher","first-page":"F2","DOI":"10.1152\/ajprenal.00614.2014","article-title":"Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea","volume":"309","author":"Bankir","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026052900265723200_bib31","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.cmet.2022.10.001","article-title":"The past, present, and future physiology and pharmacology of glucagon","volume":"34","author":"Capozzi","year":"2022","journal-title":"Cell Metab"},{"key":"2026052900265723200_bib32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10334-019-00773-z","article-title":"Renal sinus fat and renal hemodynamics: a cross-sectional analysis","volume":"33","author":"Spit","year":"2020","journal-title":"MAGMA"},{"key":"2026052900265723200_bib33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/01913120050176707","article-title":"The altered structure of renal papillary outflow tracts in obesity","volume":"24","author":"Dwyer","year":"2000","journal-title":"Ultrastruct Pathol"},{"key":"2026052900265723200_bib34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1161\/01.HYP.25.4.888","article-title":"Increased hyaluronic acid in the inner renal medulla of obese dogs","volume":"25","author":"Alonso-Galicia","year":"1995","journal-title":"Hypertension"},{"key":"2026052900265723200_bib35","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur Heart J"},{"key":"2026052900265723200_bib36","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2337\/db24-0305","article-title":"Glucagon clearance is decreased in chronic kidney disease but preserved in liver cirrhosis","volume":"73","author":"Grondahl","year":"2024","journal-title":"Diabetes"},{"key":"2026052900265723200_bib37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cmet.2023.12.024","article-title":"Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease","volume":"36","author":"Wang","year":"2024","journal-title":"Cell Metab"},{"key":"2026052900265723200_bib38","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s42003-022-04242-7","article-title":"Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression","volume":"5","author":"Bomholt","year":"2022","journal-title":"Commun Biol"},{"key":"2026052900265723200_bib39","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00088.2024","article-title":"Glucagon receptor activation contributes to the development of kidney injury","volume":"327","author":"Bomholt","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026052900265723200_bib40","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.xkme.2024.100804","article-title":"Measuring albuminuria in individuals with obesity: pitfalls of the urinary albumin-creatinine ratio","volume":"6","author":"Chagnac","year":"2024","journal-title":"Kidney Med"},{"key":"2026052900265723200_bib41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026052900265723200_bib42","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/ndt\/gfaf114","article-title":"Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"40","author":"Cherney","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf230\/65025382\/gfaf230.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/6\/1058\/65025382\/gfaf230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/6\/1058\/65025382\/gfaf230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:27:02Z","timestamp":1780028822000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/6\/1058\/8305911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf230","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,10,29]]}}}